Stryder’s Journey with Stage 4 High-Risk NeuroBlastoma – St. Baldrick’s Foundation
St. Baldrick’s Foundation shared a post on LinkedIn:
“When Stryder was diagnosed with stage 4 high-risk neuroblastoma at two years old, his family felt like their entire world stopped.
Stryder has endured multiple surgeries, stem cell transplants, and countless rounds of chemotherapy, immunotherapy, radiation, and MIBG therapy.
He is now on a clinical trial led by a St. Baldrick’s researcher, Dr. Jennifer Michlitsch, using oral chemo and DFMO as a form of disease maintenance.
His battle has been over 2.5 years long, and he continues defying the odds.
His treatment has caused hearing loss, and he may have life-long issues with his pancreas, but Stryder never lets it dull his shine.
His journey is far from over as he is still living with a tumor, but his family is grateful that it is currently stable.
Research Is Hope and you can give kids like Stryder more treatment options.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023